<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00643240</url>
  </required_header>
  <id_info>
    <org_study_id>2006LS057</org_study_id>
    <secondary_id>MT2006-09</secondary_id>
    <secondary_id>UMN-0611M96887</secondary_id>
    <nct_id>NCT00643240</nct_id>
  </id_info>
  <brief_title>Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Phase I Open Label, Single Arm Escalation Trial to Evaluate the Biodistribution and Safety of BU-12 in Patients With Advanced Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiolabeled monoclonal antibodies can find cancer cells and carry cancer-killing&#xD;
      substances to them without harming normal cells. This may be effective treatment for&#xD;
      leukemia.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the best dose of yttrium Y 90-labeled monoclonal&#xD;
      antibody BU-12 in treating patients with advanced relapsed or refractory acute lymphoblastic&#xD;
      leukemia or chronic lymphocytic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the biodistribution of indium-111 BU-12 in patients with refractory CD19+&#xD;
           leukemia.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the maximum tolerated dose of yttrium Y 90 anti-CD19 antibody BU-12&#xD;
&#xD;
        -  Determine the human anti-mouse antibody (HAMA) response.&#xD;
&#xD;
        -  To define, preliminarily, the antitumor activity of yttrium Y 90 anti-CD19 antibody&#xD;
           BU-12.&#xD;
&#xD;
      OUTLINE: Patients receive yttrium Y 90 anti-CD19 antibody BU-12/indium-111 BU-12 IV over 60&#xD;
      minutes on day 0 and undergo whole-body imaging on days 0, 1, 3, 4, and 7. Patients also&#xD;
      undergo blood collection and bone marrow biopsy periodically for dosimetry calculations and&#xD;
      pharmacokinetics.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to slow accrual&#xD;
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biodistribution of indium-111 BU-12</measure>
    <time_frame>Immediately post infusion, 4-6 hours after infusion and Days 1, 3, 4 and 7 after infusion</time_frame>
    <description>Perform a whole body scan acquiring both anterior and posterior images at a speed of 10 cm/min (20 minute scan) using a medium energy collimator, a 256 x 1024 computer acquisition matrix and acquisition photo peak settings of 172 and 247 keV with 15% windows.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum tolerated dose of yttrium Y 90 anti-CD19 antibody BU-12</measure>
    <time_frame>Beginning Day 1 of treatment</time_frame>
    <description>DLT will be defined as bone marrow aplasia &gt; 6 weeks duration from the first treatment day; specifically, failure to recover peripheral ANC &gt; 500/μL and platelets &gt; 20,000/μL documented by bone marrow aplasia, not malignant infiltration - Any NCI CTCAE v 3.0 grade 3 non-hematologic toxicity except for allergic reactions to radiolabeled BU-12 will be dose limiting. If the BU-12 antibody is very allergenic, then ≥ grade 3 allergic reactions will be dose limiting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of a human antibody to murine antibody</measure>
    <time_frame>baseline, 28 and 60 days post therapy, and at 6 months post therapy</time_frame>
    <description>Presence or absence of a human antibody to murine antibody at baseline, 28 and 60 days post therapy, and at 6 months post therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients by Clinical Response</measure>
    <time_frame>day 28 and day 60</time_frame>
    <description>Patients evaluable for DLT will be assessed for response at day 28 and day 60 post therapy dose (event is whether or not the patient has a Complete Remission, Partial Remission, Stable Disease, Refractory Disease, Relapsed Disease). The proportion of patients by disease status will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Response</measure>
    <time_frame>Day 28, 60, 6 Months</time_frame>
    <description>Time-to-event will be measured from date of therapy dose.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>111 In-BU-12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>111In-BU-12 is the 111Indium-labeled murine monoclonal antibody used for imaging and dosimetry.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 anti-CD19 monoclonal antibody BU12</intervention_name>
    <description>Patients in whom the biodistribution is as expected (unaltered) AND a HAMA response does not develop will receive a single dose of 90Y-BU-12 in a dose escalated manner to establish the maximum tolerated dose (MTD) of 90Y-BU-12 over 60 minutes on Day 0. A single course of BU-12 includes the imaging dose of 111In-BU-12 followed 7-8 days later by the therapy dose of 90YBU- 12.</description>
    <arm_group_label>111 In-BU-12</arm_group_label>
    <other_name>90Y-BU-12</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>111In-BU-12</intervention_name>
    <description>Patients receive indium-111 BU-12 IV over 60 minutes on day 0</description>
    <arm_group_label>111 In-BU-12</arm_group_label>
    <other_name>indium-111 BU-12</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed CD19-positive (&gt; 25% by flow cytometry evaluation of bone&#xD;
             marrow blasts) disease of 1 of the following types:&#xD;
&#xD;
               -  Primary refractory or relapsed acute lymphoblastic leukemia (ALL) defined as&#xD;
                  persistent disease following a minimum of two different standard effective&#xD;
                  chemotherapy induction attempts at time of diagnosis or at relapse&#xD;
&#xD;
               -  Chronic Lymphocytic leukemia (CLL) following blast crisis (≥15% bone marrow&#xD;
                  blasts following a minimum of one standard effective chemotherapy induction&#xD;
                  attempt)&#xD;
&#xD;
          -  Human anti-mouse antibody (HAMA) must be negative&#xD;
&#xD;
          -  Patients who have relapsed ≥ 60 days following an autologous or allogeneic transplant&#xD;
             are eligible if all other eligibility criteria are met&#xD;
&#xD;
          -  No active central nervous system (CNS) disease&#xD;
&#xD;
          -  ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%&#xD;
&#xD;
          -  Life expectancy &gt; 8 weeks&#xD;
&#xD;
          -  Total bilirubin ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  LVEF ≥ 45% by MUGA/ECHO&#xD;
&#xD;
          -  Oxygen saturation on room air &gt; 92% and no oxygen requirement&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients mus use effective contraception&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to of yttrium Y 90 anti-CD19 antibody BU-12 or other agents used in study&#xD;
&#xD;
          -  Uncontrolled illness including, but not limited to, any of the following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness/social situations that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
          -  HIV-positive&#xD;
&#xD;
          -  Active graft-vs-host disease&#xD;
&#xD;
          -  Less than 4 weeks since prior agents and recovered&#xD;
&#xD;
          -  Less than 7 days since prior therapy with any biologic agent, defined as a growth&#xD;
             factor or cytokine&#xD;
&#xD;
          -  Less than 3 months since prior antibody or biologic anticancer therapy (e.g.,&#xD;
             alemtuzumab or epratuzumab)&#xD;
&#xD;
          -  Other concurrent investigational agents&#xD;
&#xD;
          -  Patients with peripheral blasts &gt; 5,000/uL may receive concurrent hydroxyurea&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenda Weigel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>March 25, 2008</study_first_submitted>
  <study_first_submitted_qc>March 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2008</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

